Celldex Therapeutics’ (CLDX) “Buy” Rating Reaffirmed at Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report released on Thursday morning,Benzinga reports. They currently have a $68.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $58.00.

A number of other equities analysts have also weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Barclays increased their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Celldex Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $44.20.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $30.64 on Thursday. The company’s 50-day moving average is $25.61 and its 200-day moving average is $25.43. The firm has a market capitalization of $2.04 billion, a PE ratio of -7.88 and a beta of 1.24. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $31.31.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 39.67%. Analysts predict that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd acquired a new stake in Celldex Therapeutics during the third quarter worth about $26,000. Nisa Investment Advisors LLC increased its stake in Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 881 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Celldex Therapeutics during the third quarter valued at approximately $42,000. Russell Investments Group Ltd. raised its position in Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Celldex Therapeutics during the third quarter worth $63,000.

Key Headlines Impacting Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Completed enrollment in global Phase 3 EMBARQ program (EMBARQ‑CSU1 & EMBARQ‑CSU2) for barzolvolimab — 1,939 patients across 43 countries, the largest antihistamine‑refractory CSU program, which de‑riscales the timeline for potential 2026 data readouts. Completion of Phase 3 Enrollment
• Positive Sentiment: Analysts showing conviction: Stifel Nicolaus reaffirmed a Buy and raised its price target to $68 (previously $58) — implying ~122% upside from the current price level — which can support investor interest and buying pressure. Stifel Rating/Price Target
• Positive Sentiment: Morgan Stanley (via TipRanks summary) and other analysts have reiterated Buy ratings, citing early EMBARQ enrollment and multiple 2026 data catalysts that improve the risk/reward profile. Analyst Commentary
• Neutral Sentiment: Consensus on analyst coverage is mixed‑to‑positive — sites report an average rating around “Moderate Buy,” which supports a constructive medium‑term view but is not a unanimous bullish signal. Analyst Consensus
• Neutral Sentiment: Short interest reporting appears anomalous / immaterial in recent data (reported as zero), so it likely did not meaningfully influence today’s move. Short Interest Note
• Negative Sentiment: Q4 2025 results missed expectations: CLDX reported ($1.22) EPS vs. ($1.00) consensus and revenue of $0.12M vs. $1.53M expected — the miss increases near‑term financial uncertainty and likely drove intraday selling pressure despite the clinical progress. Earnings Press Release

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.